In a market where revolutionary treatments and new technologies threaten to introduce structural changes, the need for national authorities and regulators to adapt and catch up with the pace of the industry is of uttermost importance. Dr Catarina Andersson Forsman, director general of the Swedish Medical Products Agency (MPA), shares her unique perspective on the role that the agency must play in this regard going forward in addition to the strong commitment of Sweden to achieve the United Nation’s sustainability goals.
We must develop a system to work more efficiently with real-world data
